Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study is designed to survey the awareness rate of Chinese National Adult Lipid Treatment Guideline (2007) by cardiologists; To survey the control rate of the patients with dyslipidemia in "real world"; and to evaluate the percentage of hyperlipidemia patients who achieved target LDL-C level according to the Chinese National Adult Lipid Treatment Guideline (2007) following 8-week treatment by Crestor® 5mg or 10mg
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 1 | patients being diagnosed as dyslipidemia but not receiving Crestor® | ||
| 2 | hypercholesterolemia or mixed dyslipidemia and have been initiated treatment with Crestor® |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| the awareness rate of Chinese National Adult Lipid Treatment Guideline (2007) by cardiologists | 1 time | |
| the control rate of patients reaching target LDL-C level | 8 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| the percent change from baselines in TC, TG, HDL-C | 8 weeks | |
| the percentage of hyperlipidemia patients in different risk categories who achieved target LDL-C level according to the Chinese National Adult Lipid Treatment Guideline (2007) | 8 weeks |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Patients who has been diagnosed as hypercholesterolemia and decided by physician to use Crestor® 5mg or 10mg or other regimens (TLC or other lipid-lowering agents)
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Karen Atkin | Astrazeneca China R&D | Study Director |
| Zhu Junren | Fudan University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Research Site | Beijing | Beijing Municipality | China | |||
| Research Site |
Not provided
| ID | Term |
|---|---|
| D006949 | Hyperlipidemias |
| ID | Term |
|---|---|
| D050171 | Dyslipidemias |
| D052439 | Lipid Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Chenzhen |
| Guangdong |
| China |
| Research Site | Guangzhou | Guangdong | China |
| Research Site | Harbin | Heilongjiang | China |
| Research Site | Zhengzhou | Henan | China |
| Research Site | Nanjing | Jiangsu | China |
| Research Site | Shenyang | Liaoning | China |
| Research Site | Jinan | Shandong | China |
| Research Site | Qingdao | Shandong | China |
| Research Site | Shanghai | Shanghai Municipality | China |
| Research Site | Xi’an | Shanxi | China |
| Research Site | Chengdu | Sichuan | China |
| Research Site | Tianjin | Tianjin Municipality | China |
| Research Site | Hangzhou | Zhejiang | China |
| Reseearch Site | Ningbo | Zhejiang | China |